GW reports survival data in Phase II GBM study

GW Pharmaceuticals plc (NASDAQ:GWPH) said data from a Phase II trial showed that THC:CBD (GW42002:GW42003) significantly improved one-year

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE